Download presentation
Presentation is loading. Please wait.
Published byVivien Hopkins Modified over 9 years ago
1
“Progress Update / Disbursement Request” (PU/DR) PSM Section PSM section, R-7 Malaria Sept 17,2011
2
Progress Update / Disbursement Request (PU/DR) The ongoing progress update and disbursement request (PU/DR) is both a progress report on the latest completed period of program implementation and a request for funds for the following period of implementation. Its purpose is to provide an update of the programmatic and financial progress of a Global Fund-financed grant, as well as an update on fulfillment of conditions precedent, management actions and other requirements.
3
PU/DR submission & verification schedule The SR is required to submit the PU/DR to the PR within 20 calendar days from the closing date of the relevant progress update period. All sections of PR unit will complete the desk within 03 days after the receipt of the PU/DR. Feedback to the SRs (if any). 01 day SRs response on the PRs observation (if any).03 days Verification by the PR team (all sections). 02 days delay in process = delay in disbursement
4
Procurement and Supply Management (PSM) Overall Purpose; This section provides an update on PSM issues; 1.Status of reporting in the Price and Quality Reporting (PQR) of the procurement of certain pharmaceuticals and health products; 2.Risks of stock-out of pharmaceuticals and health products. 3.Any issues related to PSM of pharmaceuticals and health products.
5
Price and Quality Reporting (PQR) The PQR Tool is a web-based system used by TGF to collect transaction level procurement information from PR on key health products. The system’s goals are to: Communicate market information to PR, Improve transparency, Enable TGF to monitor adherence to it’s Quality Assurance Policy, Help TGF and its partners to better understand and influence the market for pharmaceutical products
6
1.General Guidance on PQR Data Entry The update of the PQR system with complete and accurate procurement related data is a prerequisite for any disbursement decision. The pharmaceuticals and health products to be reported in the PQR include ACTs, RDTs & (LLINs). The PSM section is ultimately accountable for the accuracy and completeness of procurement information for the grant in the PQR system. Upon agreement with the PR, this data can be entered in the PQR directly by SRs receiving products and invoices.
7
1.SR-Procurement Info S.NoParticulars Quantity Remarks/ Comment Opening balance at the start of quarter Received in quarter Utilization in quarter Balance at end of quarter 1LLIN's1005,8005805,320 2ACT's39500198341 3RDT's125,0501,7633,299 4Others0000 5 Fixed Assets No
8
SR to maintain the district / facility level stocks
9
SR supply management at district level Particulars Opening balance (quarter) Received in quarter Utilized in quarter End Balance (quarter) Comments ACTs 10251025Ok RDTs 100250150200Stocks to be replenished LLINs 1000500010005000Ok Others Gimsa 0.1 ltr1 ltr Fixed Assets Laptop Nil1
10
SR supply management at facility level in the district Monthly stock records should be maintained. – Balance at the start of month – Stocks delivered during the month – Stock utilized during the month – Balance at the end of month Reallocation of stocks within the district / facility will help to avoid the stock outs
11
2.Risks of stock-out of Pharmaceuticals and health products in the next period of implementation. This information will help PR to measure the level of risk of program implementation delays and treatment interruption, and highlight the need for any action to mitigate the risk. The SR should describe risks of stock-out of key Pharmaceuticals and health products at the regional / district level of the grant in the next period of implementation by taking into account the most up-to-date stock levels, consumption, forecasts and procurement planning.
12
2.Risks of stock-out of key Pharmaceuticals and health products in the next period of implementation. In cases where the described risk is substantial, the SR should indicate any mitigating measures taken or planned. NOTE:- Any scale-up or program acceleration plans need to be taken into account when assessing this risk.
13
Steps taken by PR Based on the most up-to-date information on stocks at the provincial / district level of the grant, consumption forecasts or, in their absence, other best information available to the PR, the PR should comment on the reasonableness of the SR’s description of risks of stock-outs and actions taken to address them. No additional fieldwork is required unless specifically requested by the authorities.
14
Steps taken by PR In cases where major risks are present the PR should describe the risks in the PR Findings and Recommendations Section, and make actionable recommendations to improve forecasting and procurement. The PR should discuss identified issues and recommendations with the SR.
15
3. Additional issues related to procurement and supply management. The SR should raise any issue(s) or information on the procurement and supply management of pharmaceuticals and health products that could impact program implementation.
16
Steps taken by PR The PR should comment on any additional issues related to the procurement and supply management of pharmaceuticals and health products. It should assess the impact of these issues (current and/or future) on program implementation.
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.